SEEK, based in London, is developing a broad pipeline of breakthrough medicines to address major disease areas. Its pipeline includes two novel vaccines against HIV and Flu which have successfully completed Phase II development. It is also developing differentiating low-cost small molecule drugs with short times-to-market in order to increase treatment availability for much larger patient populations. These products will be commercialised through SEEK’s infirst+ HEALTHCARE division.
